Hospital acquired infections
Patients admitted to or visiting hospitals can develop multiple infections, which are known as hospital-acquired infections (HAIs), or, simply, hospital infections. These conditions generally spread within nursing homes, dialysis centres, rehabilitation centres, outpatient surgery centres, and hospitals. Various bacterial, fungal, and viral pathogens can cause hospital infections. Intensive care units are also a common source of HAIs, which can be treated using antimicrobial drugs. Some therapeutic drugs available for these diseases are CAZ AVI, Surotomycin, MK-3415A, and Ceftolozane.
The growing susceptibility of the neonatal population to HAIs and the booming supply of drugs for these conditions is likely to lead to massive growth in the hospital infection therapeutics market in the coming years. Moreover, the lack of skilled nursing staff in healthcare settings, especially in emerging economies, is a key factor making therapeutic drugs more important. In many countries, these factors will offer pharmaceutical companies the opportunity to increase their production capacity in the coming years.
The number of hospitals is also rising worldwide, primarily due to government efforts to make healthcare more accessible. The World Bank reports the number of hospital beds per 1,000 people around the world increased to 2.894 in 2017 from 2.462 in 2005. A higher number of hospital beds means a larger number of hospital patients, which translates into a higher incidence of various HAIs. Ultimately, this will increase the demand for therapeutic drugs in the coming years.
North America has emerged as the hospital infection therapeutics market leader. The reason is the higher ratio of hospitals to the population of the region compared to other parts of the world. The surging population of ageing people in the continent and the increasing number of multi-drug-resistant microbial pathogens are also significant reasons leading to the rising demand for therapeutic drugs. APAC is also witnessing a rising demand for therapeutic drugs, especially in China and India, due to the growing prevalence of HAIs.
[edit] Related articles on Designing Buildings
Featured articles and news
Construction awards provide relief in wake of ISG collapse
Spike in major infrastructure awards, housing up but short of targets, are ISG collapse impacts yet to come.
Biodiversity net gain with related updates and terms
Only 0.5% of applications subject to BNG in the context significant proposed changes to planning.
As political power has shifted from blue to red
Has planning now moved from brown to green?
The role of construction in tackling the biodiversity crisis
New CIOB Nature of Building digital series available now.
The Nature Towns and Cities initiative
Grants of up to 1 million for local councils and partners.
The continued ISG fall out October updates
Where to look for answers to frequently asked questions.
Building safety remediation programme for Wales
With 2024 October progress updates.
In major support package for small businesses.
Conservation and transformation
Reading Ruskin’s cultural heritage. Book review.
Renovating Union Chain Bridge.
AI tools for planning, design, construction and management
A long, continually expanding list, any more to add?
Robots in the construction industry
From cultural characterisations to construction sites.
Empowering construction with AI integration
New horizons with a human touch.
Key AI related terms to be aware of
With explanations from the UK government.
A Better Hiring Toolkit for construction
Tooling up to hire under best practice standards in the sector.
Recharging Electrical Skills in Wales
Step by step collaborative solutions.
Comments
[edit] To make a comment about this article, or to suggest changes, click 'Add a comment' above. Separate your comments from any existing comments by inserting a horizontal line.